Michael W Method MD MPH, MBA
Cancer Genetics/Cancer Risk Assessment, Gynecologic Cancer, Hospice & Palliative
Associate Professor, Indiana University School of Medical Director, Division of Gynecologic Oncology
Join to view full profile
7979 N Shadeland AveSte 310Indianapolis, IN 46250
Phone+1 317-621-3780
Fax+1 317-621-3088
Dr. Method is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Notre DameMBA, 2007 - 2009
University of Miami/Jackson Health SystemFellowship, Gynecologic Oncology, 1993 - 1996
University of California (San Francisco)Residency, Obstetrics and Gynecology, 1986 - 1990- Northwestern McGaw/CMH1983 - 1986
- University of Notre DameBS, Biochemistry, High Honors, 1982 - 1986
Certifications & Licensure
IN State Medical License 1998 - 2027
MI State Medical License 1999 - 2022
MS State Medical License 1997 - 2019
AL State Medical License 1997 - 2018
FL State Medical License 1991 - 1998
IL State Medical License 1989 - 1990
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2013-2015
- Fellow (FACS) American College of Surgeons
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
- Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Publications & Presentations
PubMed
- 319 citationsMirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.Kathleen N Moore, Antoine Angelergues, Gottfried E Konecny, Yolanda García, Susana Banerjee
The New England Journal of Medicine. 2023-12-07 - 52 citationsA real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer.Kristin M Sheffield, Jessica R Peachey, Michael Method, Brenda R Grimes, Jacqueline Brown
Future Oncology. 2022-07-01 - 6 citationsA real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.Jacqueline Brown, Savannah Scardo, Michael Method, Dan Schlauch, Amanda Misch
BMC Cancer. 2022-05-06
Professional Memberships
- Member
- Member
- Society of Gynecologic OncologyFellow
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
